DSGN Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Design Therapeutics's net margin of -49.65%. Design Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 74.19%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 39.8%. Given that Design Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Design Therapeutics is more attractive than NovaBay Pharmaceuticals.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.363%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Design Therapeutics's net income of -$13.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Design Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -- compared to Design Therapeutics's net margin of -30.91%. Design Therapeutics's return on equity of -- beat PTC Therapeutics's return on equity of --.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 74.19%. On the other hand PTC Therapeutics has an analysts' consensus of $64.71 which suggests that it could grow by 19.31%. Given that Design Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Design Therapeutics is more attractive than PTC Therapeutics.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.660, suggesting its less volatile than the S&P 500 by 34.007%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than PTC Therapeutics quarterly revenues of $213.2M. Design Therapeutics's net income of -$13.7M is higher than PTC Therapeutics's net income of -$65.9M. Notably, Design Therapeutics's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 5.17x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Design Therapeutics's net margin of -2357.27%. Design Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 74.19%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 957.24%. Given that Palatin Technologies has higher upside potential than Design Therapeutics, analysts believe Palatin Technologies is more attractive than Design Therapeutics.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Design Therapeutics's net income of -$13.7M is lower than Palatin Technologies's net income of -$2.4M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -- compared to Design Therapeutics's net margin of -549.33%. Design Therapeutics's return on equity of -- beat Voyager Therapeutics's return on equity of -21.07%.

Design Therapeutics has a consensus price target of $7.33, signalling upside risk potential of 74.19%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 341.1%. Given that Voyager Therapeutics has higher upside potential than Design Therapeutics, analysts believe Voyager Therapeutics is more attractive than Design Therapeutics.

Design Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.87699999999999%.

Design Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Design Therapeutics pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Design Therapeutics quarterly revenues are --, which are smaller than Voyager Therapeutics quarterly revenues of $6.3M. Design Therapeutics's net income of -$13.7M is higher than Voyager Therapeutics's net income of -$34.5M. Notably, Design Therapeutics's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Design Therapeutics is -- versus 2.63x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.